ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
ADVENTRX To Present ANX-201 Preclinical Data At Keystone Symposia HIV Pathogenesis Conference
ADVENTRX Pharmaceuticals,
Inc. (Amex: ANX), announced that data from preclinical studies of
ANX-201, the Company's broad spectrum antiviral product candidate, has been
accepted for presentation at the Keystone Symposia HIV Pathogenesis
Conference, which takes place March 27-April 1, 2008 in Banff, Alberta. The
HIV Pathogenesis Conference is part of the Keystone Symposia Global Health
Series, which is supported by the Bill & Melinda Gates Foundation.
The poster presentation entitled "The pyrophosphate analogue
thiophosphonoformic acid confers a favorable HIV resistance profile," is
scheduled to be presented on March 30, 2008. The presentation will
highlight results of in vitro infectivity assays that demonstrate a unique
resistance profile for ANX-201 that suggests suppression of resistance to
nucleoside reverse transcriptase inhibitors (NRTIs), a commonly used class
of drugs. The potential clinical benefit of ANX-201 when used as part of
combination therapy with NRTIs in resistant HIV-infected patients will also
be discussed.
About ANX-201
ANX-201 (thiophosphonoformic acid) is a pyrophosphate analog and member
of a new class of reverse transcriptase inhibitor (RTI) for treatment of
resistant HIV-infected patients. ANX-201 has shown activity against HIV
drug-resistant clinical isolates in preclinical studies. The resistance
profile of ANX-201 is unique among approved RTIs and has been shown to
resensitize NRTI-resistant viruses. In preclinical studies, antiretroviral
activity of ANX-201 has demonstrated synergistic activity with NRTIs
suggesting potential clinical benefits of combination therapy. In other
preclinical studies, ANX-201 has shown broad-spectrum antiviral activity
against HIV-1, HIV-2, human and avian influenza viruses, and herpes simplex
viruses 1 and 2 (HSV-1 and HSV-2).
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases. The Company
seeks to improve the performance and safety of existing treatments by
addressing significant problems, such as drug metabolism and
bioavailability, excessive toxicity and treatment resistance. More
information can be found on ADVENTRX's web site at http://www.adventrx.com.
Forward Looking Statement
ADVENTRX cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks and assumptions that, if they materialize or
do not prove to be accurate, could cause ADVENTRX's results to differ
materially from historical results or those expressed or implied by such
forward-looking statements. These risks and uncertainties include, but are
not limited to: the validity of research results; the risk that preclinical
results are not indicative of the success of subsequent clinical trials and
that products will not perform as preclinical data suggests or as otherwise
anticipated; unexpected adverse side effects or inadequate therapeutic
efficacy of ADVENTRX's product candidates and other uncertainties inherent
in the drug development process; the timing and success of clinical trials;
difficulties or delays in developing, testing, manufacturing, and obtaining
regulatory approval for ADVENTRX's product candidates; the risk that
ADVENTRX will be unable to raise sufficient capital to fund the projects
necessary to meet its anticipated or stated goals and milestones; and other
risks and uncertainties more fully described in ADVENTRX's press releases
and public filings with the Securities and Exchange Commission. ADVENTRX's
public filings with the Securities and Exchange Commission are available at http://www.sec.gov.
You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date when made. ADVENTRX does not
intend to update any forward-looking statement set forth in this press
release to reflect events or circumstances arising after the date on which
it was made.
ADVENTRX Pharmaceuticals, Inc.
http://www.adventrx.com
ADVENTRX de a prezenta ANX-201 sunt disponibile date preclinice la HIV, Simpozioane Cheie de boltã patogeneza de conferinte - ADVENTRX To Present ANX-201 Preclinical Data At Keystone Symposia HIV Pathogenesis Conference - articole medicale engleza - startsanatate